Insulin 287

Drug Profile

Insulin 287

Alternative Names: 148-0287-A; Insulin-287; LAI-287; Long-acting basal insulin analogue; Long-acting-insulin-287; NN-1436; NN-1956; NNC-0148-0000-0287; OI-287GT

Latest Information Update: 08 Dec 2016

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Type 2 diabetes mellitus
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 23 Nov 2016 Novo Nordisk plans a phase I trial for Type-2 diabetes mellitus in Germany (NCT02964104)
  • 01 Nov 2016 Novo Nordisk initiates a phase I trial for Type-2 diabetes mellitus in Germany (NCT02964104)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in Germany (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top